Miller Howard Investments Inc. NY Cuts Stock Position in Pfizer Inc. (NYSE:PFE)

Miller Howard Investments Inc. NY lessened its stake in Pfizer Inc. (NYSE:PFE) by 3.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,251 shares of the biopharmaceutical company’s stock after selling 527 shares during the quarter. Miller Howard Investments Inc. NY’s holdings in Pfizer were worth $497,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. RB Capital Management LLC increased its holdings in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock worth $282,000 after acquiring an additional 341 shares in the last quarter. Ironwood Wealth Management LLC. grew its holdings in shares of Pfizer by 1.1% during the first quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock worth $1,868,000 after buying an additional 400 shares in the last quarter. United Bank grew its holdings in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after buying an additional 290 shares in the last quarter. Ergoteles LLC grew its holdings in shares of Pfizer by 136.3% during the first quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock worth $1,903,000 after buying an additional 21,209 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Pfizer by 6.4% during the first quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock worth $69,238,000 after buying an additional 79,887 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.7 %

NYSE PFE opened at $26.78 on Wednesday. The firm’s 50-day moving average is $27.33 and its two-hundred day moving average is $29.02. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $41.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a market capitalization of $151.61 billion, a P/E ratio of 74.38, a PEG ratio of 1.19 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the prior year, the company earned $1.14 earnings per share. The business’s quarterly revenue was down 41.3% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PFE. Truist Financial dropped their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, December 14th. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a report on Thursday, January 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, April 1st. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Finally, UBS Group dropped their target price on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a report on Thursday, December 14th. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.